

LFW

CUSTOMER NUMBER 25268

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Phillip Burwell et al. Attorney Docket No. CHEN0189
Serial No.: 10/799,357 Group Art Unit: 2875
Filed: March 12, 2004 Examiner:
Title: LIGHT GENERATING DEVICE TO INTRAVASCULAR USE

INFORMATION DISCLOSURE STATEMENT

Bellevue, Washington 98004

June 7, 2004

TO THE COMMISSIONER FOR PATENTS:


Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

- ☒ 1. Copies of the listed non-U.S. patent publications and other information are enclosed for the Examiner's use.
- ☐ 2. Copies of the listed patents, publications, and other information were previously cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120.
- ☐ 3. A concise explanation of the relevance of document I.D. No. _____ (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided _____.
- ☒ 4. Pursuant to 37 C.F.R. § 1.97(b), this information disclosure statement is being filed within three months of the filing date of the national application, within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits.
- ☐ 5. Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:
- a. _____ a certification as specified in 37 C.F.R. § 1.97(e); or
- b. _____ the fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$ _____ is enclosed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

6. Pursuant to 37 C.F.R. § 1.97(d), this information disclosure statement is being filed after the mailing date of either:
- a. _____ a final action under 37 C.F.R. § 1.113; or
- b. _____ a notice of allowance under 37 C.F.R. § 1.311,
- but before payment of the issue fee. The statement is accompanied by a certification as specified in 37 C.F.R. § 1.97(e), a statement requesting consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$____ is enclosed.
- X 7. Please charge any additional fees or credit any overpayment to Deposit Account No. 01-1940. A copy of this sheet is enclosed.

Respectfully submitted,




Michael C. King
Registration No. 44,832

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on June 7, 2004.

Date: June 7, 2004





CUSTOMER NUMBER 25268

INFORMATION DISCLOSURE STATEMENT LISTING SHEET

**Information Cited By Applicant(s) That May Be Material To
The Prosecution Of The Subject Application**

Applicants: Phillip Burwell et al. Attorney Docket No. CHEN0189
Serial No.: 10/799,357 Group Art Unit: 2875
Filed: March 12, 2004 Examiner:
Title: LIGHT GENERATING DEVICE TO INTRAVASCULAR USE

U.S. PATENT DOCUMENTS

NONE CITED

FOREIGN PATENT DOCUMENTS

NONE CITED

OTHER INFORMATION

<u>*Examiner</u> <u>Initial</u>	<u>Document</u> <u>No.</u>	<u>Document Information</u>
_____	O1	Nagae, T.; Aizawa, K.; Uchimura, N.' Tani, D.; Abe, M.; Fujishima, K.; Wilson, S.; and Ishimaru, S. "Endovascular Photodynamic Therapy Using Mono-L-Aspartyl-Chlorin e6 to Inhibit Intimal Hyperplasia in Balloon-Injured Rabbit Arteries," <i>Lasers in Surgery and Medicine</i> , 28:381-388 (2001). © 2001 Wiley-Liss, Inc.

Examiner's Signature

Date

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MCK/RMA:klp
6/7/2004